Peginterferon alfa-2a
- Generic Name
- Peginterferon alfa-2a
- Brand Names
- Pegasys
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 198153-51-4
- Unique Ingredient Identifier
- Q46947FE7K
- Background
Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting...
- Indication
Peginterferon alfa-2a is indicated for the treatment of HCV in combination with other antiviral drugs in patients over 5 years of age with compensated liver disease . May be used as a monotherapy in patients with contraindications to or significant intolerance to other anti-viral therapies.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Chronic Hepatitis C Virus (HCV) Infection, HBeAg Positive Chronic Hepatitis B
- Associated Therapies
- -
The Changes of Natural Killer Cells Frequency and Function During Antiviral Therapy
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Beijing Ditan Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03208998
- Locations
- 🇨🇳
Beijing Ditan hospital,Capital Medical University, Beijing, Beijing, China
Long-term Benefit in Chronic Hepatitis B Patients After Standard Peginterferon Alfa Therapy
- First Posted Date
- 2017-06-08
- Last Posted Date
- 2021-04-13
- Lead Sponsor
- Xiamen Amoytop Biotech Co., Ltd.
- Target Recruit Count
- 473
- Registration Number
- NCT03181113
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Second Affiliated Hospital Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳Southwest Hospital, Chongqing, Chongqing, China
A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects
- Conditions
- Interventions
- First Posted Date
- 2017-04-24
- Last Posted Date
- 2017-10-16
- Lead Sponsor
- Alios Biopharma Inc.
- Registration Number
- NCT03125213
The Investigation of Peginterferon Alfa-2a on Optimal in Chronic Hepatitis B Patients Who Have a High Risk of HCC
- Conditions
- Interventions
- First Posted Date
- 2017-03-20
- Last Posted Date
- 2017-05-03
- Lead Sponsor
- Shanghai Nanhui Nanhua Hospital
- Target Recruit Count
- 150
- Registration Number
- NCT03084250
- Locations
- 🇨🇳
Nanhua Hospital, Shanghai, China
Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 141
- Registration Number
- NCT03020082
Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II
- Conditions
- Interventions
- First Posted Date
- 2017-01-13
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Ascletis Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 70
- Registration Number
- NCT03020004
Peg-interferon for Inactive Chronic Hepatitis B Carriers
- Conditions
- Interventions
- First Posted Date
- 2016-12-14
- Last Posted Date
- 2019-03-19
- Lead Sponsor
- Seng Gee Lim
- Target Recruit Count
- 90
- Registration Number
- NCT02992704
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
A Study to Evaluate Addition of Peginterferon Alfa-2a to Chronic Hepatitis B (CHB) Patients Treated With NAs
- First Posted Date
- 2016-09-09
- Last Posted Date
- 2016-09-12
- Lead Sponsor
- Henan Provincial People's Hospital
- Target Recruit Count
- 114
- Registration Number
- NCT02894918
- Locations
- 🇨🇳
Weishi County People's Hospital, Kaifeng, Henan, China
🇨🇳Henan People's Hospital, Zhengzhou, Henan, China
🇨🇳Shangqiu No.1 People's Hospital, Shangqiu, Henan, China
A Study of Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) Combination Therapy in Participants With Chronic Hepatitis C (CHC) and Various Degrees of Renal Impairment
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2016-08-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 63
- Registration Number
- NCT02864199
A Study of Continued Treatment Among Participants Who Have Responded to Peginterferon Alfa-2a (Pegasys®) or Recombinant Interferon Alfa-2a (Roferon-A®) in Prior Clinical Studies
- Conditions
- Interventions
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 9
- Registration Number
- NCT02829775
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.